產學研發-EN

Technology Available for Industry-Academia Collaboration or Technology Licensing. “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (2022/01/03)

1. Title: NHRI technology, “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: Amplification or overexpression of MYC oncoproteins, master regulator of cancers, are observed in over 28% common cancer types. The Technology is a novel aurora kinase inhibitor which was …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (2022/01/03) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR211: a peripheral CB1 receptor antagonist”(2018/12/17)

Title: NHRI technology, “DBPR211: a peripheral CB1 receptor antagonist” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description: Cannabinoid receptor 1 (CB1) is expressed in several peripheral tissues related to metabolic control and its dysregulation contributes to metabolic disorders. DBPR211 is a highly selective antagonist of peripheral CB1 receptors. It exhibits beneficial …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR211: a peripheral CB1 receptor antagonist”(2018/12/17) Read More »